Immunogenicity and Safety of Heterologous Combinations of COVID-19 Vaccines Available Under Emergency Use Authorization in Pakistan: A Randomized Phase II Trial
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Acronyms COMBAT-COVID
Most Recent Events
- 22 Feb 2022 New trial record